此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

非缺血性扩张型心肌病患者经心内膜注射同种异体 MSC (DCMII)

2026年9月28日 更新者:Joshua M Hare

一项 IIB 期随机、安慰剂对照、多中心研究,比较经内膜注射同种异体 MSC 与安慰剂治疗非缺血性扩张型心肌病患者的疗效和安全性

The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.

研究概览

研究类型

介入性

注册 (实际的)

107

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Stanford、California、美国、94304
        • Stanford University
    • Florida
      • Miami、Florida、美国、33136
        • University of Miami Miller School of Medicine
    • Kentucky
      • Louisville、Kentucky、美国、40202
        • University of Louisville
    • Texas
      • Houston、Texas、美国、77030
        • Texas Heart Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Men and women aged 18 to 80 years (inclusive) at the time of signing the informed consent form.
  2. Diagnosis of NIDCM with left ventricular ejection fraction ≤45%.
  3. Appropriate guideline-directed optimal medical therapy for non-ischemic cardiomyopathy. At a minimum, subjects must be on beta blockers and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) or Angiotensin Receptor Neprilysin Inhibitors (ARNI) or have appropriate medical indication precluding use of one or both of these agents. Subjects must be on a stable regimen for at least 30 days prior to the procedure. Dose titration is allowed.
  4. Be a candidate for cardiac catheterization*
  5. Be willing to undergo DNA test.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Be eligible for or require standard-of-care surgical or percutaneous intervention for the treatment of non-ischemic dilated cardiomyopathy

  2. Clinical manifestation of coronary artery disease (CAD) (e.g., chest pain and concomitant clinical findings such as electrocardiogram changes suggestive of coronary ischemia, myocardial infarction) or evidence of endocardial or transmural scar on cardiac MRI suggestive of undiagnosed CAD or history of percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). Be indicated for or require coronary artery revascularization

  3. Documented presence of epicardial stenosis of 70% or greater in one or more major epicardial coronary arteries

  4. Valvular heart disease including 1) aortic valve prosthesis, mechanical mitral valve, and mitral valve clip; 2) severe aortic valve insufficiency/regurgitation within 12 months of consent*

  5. Aortic stenosis with valve area ≤ 1.5cm2*

  6. Cardiomyopathy due to acute Post-partum (within 6 months), Non-compaction*, or Hypertrophic* cardiomyopathy

  7. Cardiomyopathy due to known toxin (e.g amyloid) Note: anthracycline induced cardiomyopathy will be allowed

  8. QTc interval > 550 ms on baseline electrocardiogram (ECG) (note: QTc interval is the interval between the start of the Q wave and the end of the T wave in the heart's electrical cycle)

  9. Automated Implantable Cardioverter Defibrillator (AICD) appropriate firing or anti tachycardia pacing for ventricular tachycardia or ventricular fibrillation within 30 days prior to consent

  10. Have an estimated baseline glomerular filtration rate below the clinical site's institutional cutoff

  11. A hematologic abnormality during baseline testing as evidenced by hemoglobin < 9 g/dl; hematocrit < 30%; absolute neutrophil count < 2,000 or total WBC count more than 2 times upper limit of normal; or platelet values < 100,000/ul

  12. Have liver dysfunction, as evidenced by enzymes Aspartate Transaminase Enzyme (AST) and Alanine Aminotransferase Enzyme (ALT) greater than three times the ULN

  13. Have a bleeding diathesis or coagulopathy (International Normalised Ratio (INR) > 1.5), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions

  14. Be a solid organ transplant recipient. This does not include prior cell based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting.

  15. Have a history of organ or cell transplant rejection

  16. Have a clinical history of malignancy within the past 12 months (i.e., subjects with prior malignancy must be disease free for 12 months), except curatively treated basal cell or squamous cell carcinoma or cervical carcinoma

  17. Drug and/or alcohol abuse or dependence within the past 9 months

  18. Be serum positive for HIV, hepatitis B surface antigen, or viremic hepatitis C

  19. Documented presence of a known Left Ventricular (LV) thrombus, aortic dissection, or aortic aneurysm. (Refer to "Guidance to the PI" section with regards to LV thrombus, below)*

  20. Blood glucose levels (HbA1c) >10%

  21. Severe radiographic contrast allergy

  22. Known history of anaphylactic reaction to penicillin or streptomycin

  23. Hypersensitivity to dimethyl sulfoxide (DMSO)

  24. Non-cardiac condition with life expectancy < 1 year

  25. Acute stroke or transient ischemic attack within 3 months of enrollment

  26. Be pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods

  27. Pacemaker-dependence with an Implantable Cardioverter Defibrillator (ICD) (Note: pacemaker-dependent candidates without an ICD are not excluded)

  28. Presence of a pacemaker and/or ICD generator with any of the following limitations/conditions:

    • manufactured before the year 2000
    • leads implanted < 6 weeks prior to consent
    • non-transvenous epicardial or abandoned leads
    • subcutaneous ICDs
    • leadless pacemakers
  29. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent

  30. Other MRI contraindications (e.g. subject body habitus incompatible with MRI)

  31. Need for advanced heart failure therapy (e.g. IV inotropes)

  32. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial

  33. Any other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up

(*) Applies to subjects receiving product via transendocardial administration only

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Genotype A administered with placebo Group

Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.

Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

实验性的:Genotype A administered with hMSC Group

Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.

allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

安慰剂比较:Genotype B administered with placebo Group

Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.

Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

实验性的:Genotype B administered with hMSC Group

Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.

allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

安慰剂比较:Genotype C administered with placebo Group

Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.

Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

实验性的:Genotype C administered with hMSC Group

Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention.

allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in LVEF
大体时间:Baseline, 12 months

Change in Left Ventricular Ejection Fraction (LVEF) as assessed via cardiac Magnetic Resonance Imaging (MRI)

Baseline, 12 months

次要结果测量

结果测量
措施说明
大体时间
Change in global ventricular strain
大体时间:Baseline, 12 months

Change in global ventricular strain as assessed via cardiac Harmonic Phase (HARP) MRI

Baseline, 12 months
Change in left regional strain
大体时间:Baseline, 12 months

Change in regional ventricular strain as assessed via cardiac HARP MRI

Baseline, 12 months
Left ventricular function concordance
大体时间:12 months

The left ventricular function concordance will be measured as the Number of individuals who experienced an increase in left ventricular ejection fraction (LVEF) and a simultaneous decrease in both left ventricular end systolic volume index (LVESVI) and left ventricular end diastolic volume index (LVEDVI)

12 months
Change in LVEDVI
大体时间:Baseline, 12 months

Change in left ventricular end diastolic index (LVEDVI) as assessed via cardiac MRI

Baseline, 12 months
Change in LVESVI
大体时间:Baseline, 12 months

Change in left ventricular end systolic index (LVESVI) as assessed via cardiac MRI

Baseline, 12 months
Change in Maximal oxygen consumption (peak VO2)
大体时间:Baseline, 12 months

Change in maximal oxygen consumption (peak VO2) as assessed via treadmill

Baseline, 12 months
Change in Exercise tolerance
大体时间:Baseline, 12 months

Change in exercise tolerance as assessed as the distance covered via the six-minute walk test

Baseline, 12 months
Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score
大体时间:Baseline, 12 months

Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a 21-item questionnaire with a total score ranging from 0 to 105 with lower scores indicative of better outcome.

Baseline, 12 months
Change in New York Heart Association (NYHA) Class
大体时间:Baseline, 12 months

NYHA Classifications of heart failure are as follows: Class I (no limitations); Class II (mild symptoms); Class III (marked limitations); Class IV (Severe limitations)

Baseline, 12 months
Percent change in flow mediated diameter
大体时间:Baseline, 12 months

Change in endothelial function will be reported as the percent change in flow mediated diameter assessed via flow mediated dilation (FMD).

Baseline, 12 months
Change in EPC-CFU
大体时间:Baseline, 12 months

Change in endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay

Baseline, 12 months
Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
大体时间:Baseline, 12 months

Change in NT-proBNP as assessed via blood draw

Baseline, 12 months
Incidence of MACE
大体时间:12 months

Safety will be reported as the incidence of Major Adverse Cardiac Events (MACE) assessed by treating physician

12 months
Incidence of TE-SAEs
大体时间:Day 30

Safety will be reported as the incidence of Treatment Emergent Serious Adverse Events (TE-SAEs) assessed by treating physician

Day 30

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Joshua Hare, MD、University of Miami

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年5月7日

初级完成 (估计的)

2027年4月1日

研究完成 (估计的)

2027年4月1日

研究注册日期

首次提交

2020年7月15日

首先提交符合 QC 标准的

2020年7月15日

首次发布 (实际的)

2020年7月20日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • 20200566
  • CDMRP-PR191597 (其他赠款/资助编号:US Department of Defense)
  • 20-02-134 (其他标识符:BRANY IRB)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅